Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

NCT06449001 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Paroxysmal Nocturnal Hemoglobinuria
PNH
Extravascular Hemolysis

Interventions

DRUG: Danicopan

Sponsor

Alexion Pharmaceuticals, Inc.

Collaborators

[object Object]